Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.68 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.68 |
| ▸ | SCN4A | P35499 | 1/20 | 0.63 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244984 | 0.92 | SCN9A (0.66) | SCN9ASCN5AKCNH2SCN4ASCN3A | |
| SCHEMBL3239082 | 0.91 | SCN9A (0.61) | SCN9ASCN5AKCNH2SCN4ASCN3A | |
| SCHEMBL3247845 | 0.91 | SCN9A (0.78) | SCN9ASCN5AKCNH2SCN4ASCN3A | |
| SCHEMBL3118534 | 0.89 | SCN9A (0.68) | SCN9ASCN5AKCNH2SCN4ASCN3A | |
| SCHEMBL3240652 | 0.89 | SCN9A (0.60) | SCN9ASCN5AKCNH2SCN4ASCN3A | |
| SCHEMBL3240647 | 0.89 | SCN9A (0.60) | SCN9ASCN5AKCNH2SCN4ASCN3A | |
| SCHEMBL3253423 | 0.88 | SCN9A (0.58) | SCN9ASCN5AKCNH2SCN4ASCN3A | |
| SCHEMBL3242606 | 0.87 | SCN9A (0.67) | SCN9ASCN5AKCNH2SCN4ASCN3A | |
| SCHEMBL3239650 | 0.87 | SCN9A (0.77) | SCN9ASCN5AKCNH2 | |
| SCHEMBL3246906 | 0.87 | SCN9A (0.63) | SCN9ASCN5AKCNH2SCN4ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20160089375-A1 | TOPICAL OCULAR ANALGESIC AGENTS | NOVARTIS AG (CH) | 2016-03-31 | — | — | US | disclosed |
| US-9187468-B2 | Topical ocular analgesic agents | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| WO-2014127116-A1 | TOPICAL OCULAR ANALGESIC AGENTS | NOVARTIS AG (CH) | 2014-08-21 | — | — | WO | disclosed |
| US-20140228338-A1 | TOPICAL OCULAR ANALGESIC AGENTS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160089375-A1 | TOPICAL OCULAR ANALGESIC AGENTS | OPRK1, OPRL1, QDPR | SCN9A 1714/4885SCN5A 347/4885KCNH2 796/4885 |
| US-20140228338-A1 | TOPICAL OCULAR ANALGESIC AGENTS | PDE6C, PDE6A, PDE6H | SCN9A 1931/4885SCN5A 207/4885KCNH2 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.